The United Kingdom and Ireland Vasculitis Registry: Cross-sectional data on the first 3195 patients with a focus on anti-neutrophil cytoplasm – associated vasculitis and giant cell arteritis

The United Kingdom and Ireland Vasculitis Registry: Cross-sectional data on the first 3195 patients with a focus on anti-neutrophil cytoplasm – associated vasculitis and giant cell arteritis

Detalhes bibliográficos
Principais autores:	Luqmani, R, Craven, A, Sznajd, J, Basu, N, Barrett, J, Jayne, D, Lanyon, P, Little, M, Robson, J, Robson, M, Salama, A, Watts, R
Formato:	Conference item
Publicado em:	Oxford University Press 2017

Registros relacionados

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
por: Luqmani, R, et al.
Publicado em: (2017)

276 The short-term damage burden in vasculitis and vasculitis mimics as measured by the vasculitis damage index
por: Floris, A, et al.
Publicado em: (2016)

284 Differences in early damage patterns in various forms of primary systemic vasculitis
por: Wawrzycka-Adamczyk, K, et al.
Publicado em: (2016)

Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS)
por: Nakagomi, D, et al.
Publicado em: (2017)

Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?
por: Seeliger, B, et al.
Publicado em: (2017)

Using the Birmingham Vasculitis Activity Score as a Screening Tool in Patients with Suspected Vasculitis
por: Floris, A, et al.
Publicado em: (2016)

OP0055 Using the Birmingham Vasculitis Activity Score as a screening tool in patients with suspected vasculitis
por: Floris, A, et al.
Publicado em: (2016)

The need for diagnostic criteria in systemic vasculitis
por: Suppiah, R, et al.
Publicado em: (2011)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
por: Mukhtyar, C, et al.
Publicado em: (2006)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
por: Pearce, F, et al.
Publicado em: (2017)

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
por: Guerry, M, et al.
Publicado em: (2012)

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
por: Flossmann, O, et al.
Publicado em: (2006)

Outcome measures in ANCA-associated vasculitis.
por: Suppiah, R, et al.
Publicado em: (2010)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
por: Suppiah, R, et al.
Publicado em: (2011)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
por: Mukhtyar, C, et al.
Publicado em: (2008)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
por: Basu, N, et al.
Publicado em: (2014)

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Robson, J, et al.
Publicado em: (2017)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
por: Yew, S, et al.
Publicado em: (2012)

Advances in the classification of primary systemic vasculitis
por: Suppiah, R, et al.
Publicado em: (2009)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
por: Luqmani, R, et al.
Publicado em: (2017)

Cutaneous manifestations of ANCA-associated vasculitis
por: Chiesafuxench, Z, et al.
Publicado em: (2016)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
por: Yew, S, et al.
Publicado em: (2012)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
por: Hellmich, B, et al.
Publicado em: (2007)

ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS).
por: Craven, A, et al.
Publicado em: (2013)

Assessment of systemic vasculitis.
por: Miller, A, et al.
Publicado em: (2008)

REVIEW OF THE EXPERT PANEL METHODOLOGY IN THE DIAGNOSTIC AND CLASSIFICATION CRITERIA FOR VASCULITIS STUDY: A PILOT STUDY
por: Pante, C, et al.
Publicado em: (2014)

Review Of The Expert Panel Methodology In The Diagnostic and Classification Criteria For Vasculitis Study: A Pilot Study
por: Ponte, C, et al.
Publicado em: (2013)

Arteritis macular: ¿una vasculitis benigna?
por: José González-Fernández, et al.
Publicado em: (2024-01-01)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
por: Alan D. Salama
Publicado em: (2020-01-01)

To prophylax or not to prophylax? The role of trimethoprim/sulfamethoxazole as a prophylactic agent in systemic vasculitis: the case of antineutrophil cytoplasmic antibody- associated vasculitis and giant cell arteritis
por: Alessandro Tomelleri, et al.
Publicado em: (2025-02-01)

Predictors of renal involvement in ANCA associated vasculitis
por: Kronbichler, A, et al.
Publicado em: (2018)

The European Vasculitis Society 2016 meeting report
por: Bajema, IM, et al.
Publicado em: (2017)

Vasculitis: an update.
por: Luqmani, R
Publicado em: (2014)

Vasculitis: an update.
por: Luqmani, R
Publicado em: (2014)

Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.
por: Jayne, DR, et al.
Publicado em: (1997)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
por: Merkel, P, et al.
Publicado em: (2009)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
por: Robson, J, et al.
Publicado em: (2017)

Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases
por: Ponte, C, et al.
Publicado em: (2014)

Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases.
por: Ponte, C, et al.
Publicado em: (2014)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
por: Robson, J, et al.
Publicado em: (2014)